A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors

Clinical trial NCT06848699 · RECRUITING

Trial details

NCT number: NCT06848699
Sponsor: Shanghai Henlius Biotech
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Solid Tumor Cancer Non Small Cell Lung Cancer

Start date: 2025-02-25
Primary completion: 2026-10-30
Enrollment: 105

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.